Some people should not explore this at all, at least not outside a clinical trial
Confounding factors further complicate interpretation
The results of clinical trials indicate that this may make it more effective for weight loss when compared to otherapproved drugs like Wegovy (semaglutide), which targets one hormone, and Mounjaro (tirzepatide), which targets two
They are unlikely to be as low as the MSF calculates because biosimilars are much more expensive to develop than generic medicines
Compounded medications are prepared by licensed pharmacies as prescribed by healthcare providers, and their safety and efficacy have not been evaluated by the FDA
In addition, as new agents enter the market, payer coverage and prior-authorization landscapes will shiftespecially with expanded medication benefits